| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA031046 |
| P8608 | Fatcat ID | release_plhs3s6xkveb5dxdr54qzp6ghy |
| P698 | PubMed publication ID | 15084693 |
| P50 | author | Robert Tibshirani | Q3938444 |
| Jonathan R. Pollack | Q73921770 | ||
| Eric Bair | Q55483301 | ||
| Hartmut Döhner | Q66385451 | ||
| Konstanze Döhner | Q66385457 | ||
| P2093 | author name string | Lars Bullinger | |
| Richard F Schlenk | |||
| Stefan Fröhling | |||
| P2860 | cites work | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| adult acute myeloid leukemia | Q53673331 | ||
| P304 | page(s) | 1605-1616 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia | |
| P478 | volume | 350 |
| Q38269954 | (Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia |
| Q33526362 | 3'-end sequencing for expression quantification (3SEQ) from archival tumor samples |
| Q50609353 | A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients. |
| Q33298689 | A Marfan syndrome gene expression phenotype in cultured skin fibroblasts |
| Q58614591 | A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs |
| Q35049524 | A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers |
| Q53301957 | A cancer fate in the hands of a samurai |
| Q37420280 | A combinatory approach for selecting prognostic genes in microarray studies of tumour survivals |
| Q57634693 | A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia |
| Q37041909 | A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects |
| Q38695117 | A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. |
| Q57270609 | A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials |
| Q56744221 | A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia |
| Q35582360 | A multigene array for measurable residual disease detection in AML patients undergoing SCT |
| Q37563126 | A network-assisted co-clustering algorithm to discover cancer subtypes based on gene expression |
| Q37898108 | A new frontier in personalized cancer therapy: mapping molecular changes. |
| Q33314438 | A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments |
| Q52001471 | A new paradigm for profiling testicular gene expression during normal and disturbed human spermatogenesis |
| Q40339485 | A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42. |
| Q64096008 | A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study |
| Q35916012 | A perspective on DNA microarrays in pathology research and practice |
| Q36453350 | A shared gene-expression signature in innate-like lymphocytes |
| Q37433446 | A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report |
| Q34212654 | AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias |
| Q54676893 | AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. |
| Q54495799 | AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. |
| Q38033116 | AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches |
| Q37857869 | Abnormalities of DNA repair mechanisms in common hematological malignancies |
| Q58481811 | Acute Myeloid Leukemia |
| Q38027047 | Acute Myeloid Leukemia with Normal Cytogenetics |
| Q41973082 | Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications |
| Q36663603 | Acute myeloid leukaemia |
| Q39448082 | Acute myeloid leukemia: leukemia stem cells write a prognostic signature. |
| Q88548727 | Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial |
| Q34598109 | Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia |
| Q36223607 | Advances in the molecular genetics of acute leukemia |
| Q26996818 | Allogeneic stem cell transplantation in first complete remission |
| Q46515733 | Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance |
| Q34197535 | An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia |
| Q36629521 | An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. |
| Q33712480 | An optimized protocol for microarray validation by quantitative PCR using amplified amino allyl labeled RNA |
| Q30488013 | Analyse multiple disease subtypes and build associated gene networks using genome-wide expression profiles |
| Q55526235 | Analysis of AML Genes in Dysregulated Molecular Networks |
| Q33504376 | Analysis of AML genes in dysregulated molecular networks |
| Q33254332 | Analysis of promoter regions of co-expressed genes identified by microarray analysis |
| Q48395885 | Annotation-based distance measures for patient subgroup discovery in clinical microarray studies |
| Q43461214 | Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect |
| Q36208342 | Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients |
| Q37437233 | Applications of microarray technology to Acute Myelogenous Leukemia |
| Q30490446 | Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia |
| Q33873844 | Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. |
| Q41836113 | Assumption Adequacy Averaging as a Concept to Develop More Robust Methods for Differential Gene Expression Analysis. |
| Q55664994 | BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia. |
| Q54623486 | Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. |
| Q36085026 | Biology and management of relapsed acute myeloid leukaemia. |
| Q34307027 | Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia |
| Q37451562 | Blood-based transcriptomics: leukemias and beyond |
| Q61757221 | CARD15 Status and Familial Predisposition for Crohn's Disease and Colonic Gene Expression |
| Q57599456 | CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles |
| Q38090088 | Cancer gene expression signatures – The rise and fall? |
| Q35942318 | Cancer survival analysis using semi-supervised learning method based on Cox and AFT models with L1/2 regularization |
| Q37207347 | Candidate List of yoUr Biomarker (CLUB): A Web-based Platform to Aid Cancer Biomarker Research |
| Q52927291 | Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. |
| Q33680301 | Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11. |
| Q40389129 | Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin |
| Q92463219 | Characterization of upregulated adhesion GPCRs in acute myeloid leukemia |
| Q35012779 | Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay |
| Q38904250 | Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders |
| Q92351218 | Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia |
| Q37331218 | Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations |
| Q37738442 | Clinical implications of gene expression profiling of acute myeloid leukemia |
| Q37363129 | Clinical implications of molecular genetic aberrations in acute myeloid leukemia |
| Q28301344 | Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review |
| Q35615901 | Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? |
| Q41508288 | Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group |
| Q42591389 | Clustering algorithms: on learning, validation, performance, and applications to genomics. |
| Q42010591 | Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias |
| Q42114434 | Commonly dysregulated genes in murine APL cells |
| Q54295585 | Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. |
| Q36519015 | Comparative and integrative functional genomics of HCC. |
| Q80353196 | Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model |
| Q43121205 | Comparative proteomics in acute myeloid leukemia |
| Q40279015 | Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias |
| Q83948553 | Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks |
| Q37919105 | Constitutional trisomy 8p11.21-q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia |
| Q35234867 | Control of asymmetric Hopfield networks and application to cancer attractors |
| Q40094852 | Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis |
| Q33576324 | Coordinated modular functionality and prognostic potential of a heart failure biomarker-driven interaction network |
| Q36783304 | Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML |
| Q30477879 | Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables |
| Q24811346 | Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes |
| Q94101610 | Current Awareness on Comparative and Functional Genomics |
| Q36539598 | Current therapeutic strategies for acute myeloid leukaemia |
| Q37797467 | DNA Methylation Profiling in Acute Myeloid Leukemia: From Recent Technological Advances to Biological and Clinical Insights |
| Q41879063 | DNA methylation dynamics during in vivo differentiation of blood and skin stem cells |
| Q80008501 | DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups |
| Q24644436 | DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome |
| Q35892040 | DNA-microarray analysis of brain cancer: molecular classification for therapy |
| Q34335004 | Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias |
| Q34630291 | Decoding global gene expression programs in liver cancer by noninvasive imaging |
| Q46086559 | Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis |
| Q42654933 | Densely interconnected transcriptional circuits control cell states in human hematopoiesis |
| Q47808353 | Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. |
| Q39188673 | Deregulation of protein phosphatase expression in acute myeloid leukemia |
| Q35953479 | Derivation of a fifteen gene prognostic panel for six cancers. |
| Q36720677 | Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays |
| Q42409849 | Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients |
| Q86395645 | Development of genomic markers that predict response to molecularly targeted antileukemic therapy |
| Q46516275 | Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients |
| Q35052730 | Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. |
| Q33647672 | Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling |
| Q60947640 | Dissecting the Immune Landscape of Acute Myeloid Leukemia |
| Q30845649 | Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis |
| Q33495581 | Dissection of the transformation of primary human hematopoietic cells by the oncogene NUP98-HOXA9 |
| Q45240539 | Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype |
| Q36141686 | Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. |
| Q36926841 | Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. |
| Q52721762 | Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. |
| Q21144312 | Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia |
| Q35003666 | Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics |
| Q37097180 | Dysregulated gene expression networks in human acute myelogenous leukemia stem cells |
| Q35000629 | E2F4 regulatory program predicts patient survival prognosis in breast cancer |
| Q35381542 | ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML. |
| Q36057626 | EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. |
| Q33772607 | Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia |
| Q36817144 | Early gene expression of acute myeloid leukemia in response to chemotherapy |
| Q79906767 | East and west together. Abstracts of the Leukemia and Lymphoma Meeting. Dubrovnik, Croatia. September 15-19, 2007 |
| Q33846983 | Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif |
| Q34548156 | Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells |
| Q38740919 | Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential |
| Q53341099 | Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells |
| Q37342223 | Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation |
| Q34542996 | Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia |
| Q34627568 | Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia |
| Q33209668 | Expression genomics and cancer biology |
| Q33745000 | Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients. |
| Q42515217 | Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression |
| Q33289178 | False discovery rate paradigms for statistical analyses of microarray gene expression data |
| Q91584685 | Five extracellular matrix-associated genes upregulated in oral tongue squamous cell carcinoma: An integrated bioinformatics analysis |
| Q36971233 | Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patients |
| Q34778928 | Frequency and implications of discordant gene expression profile class in posterior uveal melanomas sampled by fine needle aspiration biopsy |
| Q36062301 | Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia |
| Q34184598 | Functional proteomic profiling of AML predicts response and survival |
| Q36257547 | GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy |
| Q40022463 | GFI1 as a novel prognostic and therapeutic factor for AML/MDS. |
| Q36322508 | Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia |
| Q37632815 | Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types |
| Q33293342 | Gene expression assays |
| Q38331348 | Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. |
| Q47427446 | Gene expression profiles and protein‑protein interaction networks during tongue carcinogenesis in the tumor microenvironment. |
| Q33231820 | Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. |
| Q38510554 | Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. |
| Q37858877 | Gene expression profiling in MDS and AML: potential and future avenues. |
| Q84562440 | Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML |
| Q47235517 | Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. |
| Q46790741 | Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status |
| Q35848938 | Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction |
| Q40428994 | Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. |
| Q24814730 | Gene expression profiling predicts survival in conventional renal cell carcinoma |
| Q36050530 | Gene expression profiling using RNA extracted from whole blood: technologies and clinical applications |
| Q33538325 | Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. |
| Q47569368 | Genes and pathways associated with the occurrence of malignancy in benign lymphoepithelial lesions |
| Q33415379 | Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia |
| Q53488661 | Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics |
| Q38044773 | Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? |
| Q33555627 | Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia |
| Q33813024 | Genome-wide analysis of transcriptional reprogramming in mouse models of acute myeloid leukaemia |
| Q37406963 | Genomic approaches to small molecule discovery |
| Q38223490 | Genomic characterization of acute leukemias |
| Q38112045 | Genomics and Proteomics of Pulmonary Vascular Disease |
| Q40391459 | Genomics in multiple myeloma: biology and clinical implications. |
| Q37452405 | Genomics of pulmonary arterial hypertension: implications for therapy |
| Q33555287 | Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients |
| Q34276961 | Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes |
| Q53325167 | Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? |
| Q41901150 | H2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia |
| Q38414739 | HCsnip: An R Package for Semi-supervised Snipping of the Hierarchical Clustering Tree |
| Q37176769 | HOX expression patterns identify a common signature for favorable AML. |
| Q43065853 | HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy |
| Q35249211 | Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype |
| Q37207320 | Hematopoietic Lineage Transcriptome Stability and Representation in PAXgene Collected Peripheral Blood Utilising SPIA Single-Stranded cDNA Probes for Microarray |
| Q47869431 | Hematopoietic Stem Cells: Normal Versus Malignant. |
| Q26828941 | Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature |
| Q35249294 | Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia |
| Q35170920 | Hierarchy in gene expression is predictive of risk, progression, and outcome in adult acute myeloid leukemia |
| Q39587664 | High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia |
| Q38301831 | High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. |
| Q90648227 | High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia |
| Q24652901 | High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples |
| Q38081953 | High‐throughput on‐chip leukemia diagnosis |
| Q44260073 | Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias |
| Q28730753 | Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections |
| Q38288838 | Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability |
| Q33729914 | Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. |
| Q35607293 | IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells |
| Q36678141 | Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study |
| Q38309335 | Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes. |
| Q40239647 | Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia |
| Q42536335 | Identification of gene networks associated with acute myeloid leukemia by comparative molecular methylation and expression profiling |
| Q40168272 | Identification of genes with abnormal expression changes in acute myeloid leukemia |
| Q35989408 | Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group |
| Q38010349 | Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance |
| Q53879864 | Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. |
| Q38342048 | Identification of new markers discriminating between myeloid and lymphoid acute leukemia |
| Q35114704 | Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. |
| Q37596249 | Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. |
| Q88765096 | Identification of relevant subtypes via preweighted sparse clustering |
| Q30697080 | Identification of significant features in DNA microarray data |
| Q38694866 | Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. |
| Q60170385 | Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemia |
| Q42724137 | Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse |
| Q79139041 | Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups |
| Q91708711 | Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy |
| Q42696721 | Improved prediction of breast cancer outcome by identifying heterogeneous biomarkers |
| Q28475341 | In Vitro Transformation of Primary Human CD34+ Cells by AML Fusion Oncogenes: Early Gene Expression Profiling Reveals Possible Drug Target in AML |
| Q34137584 | In silico models of cancer |
| Q64261228 | Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients |
| Q31043701 | Independent component analysis reveals new and biologically significant structures in micro array data |
| Q35848995 | Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study |
| Q31150308 | Indirect genomic effects on survival from gene expression data |
| Q37226494 | Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia |
| Q40956513 | Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia |
| Q36117938 | Integrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information |
| Q33538043 | Integrative meta-analysis of differential gene expression in acute myeloid leukemia |
| Q37442649 | Interactive diagnostics in the indication to allogeneic SCT in AML. |
| Q33585433 | Internal validation inferences of significant genomic features in genome-wide screening |
| Q33303056 | Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome |
| Q39762784 | Invited commentary: dietary pattern analysis |
| Q33491557 | Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia |
| Q33270272 | Leukemia-targeting ligands isolated from phage-display peptide libraries. |
| Q83425187 | Liquid Tumors in the Elderly |
| Q38288626 | Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization |
| Q40327201 | Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein |
| Q33928495 | Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology |
| Q26746104 | Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? |
| Q36203024 | Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization |
| Q35719918 | Metagene projection for cross-platform, cross-species characterization of global transcriptional states |
| Q36437006 | MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia |
| Q37738573 | MicroRNA expression in acute myeloid leukemia |
| Q36288982 | MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia |
| Q33691247 | MicroRNAs expression signatures are associated with lineage and survival in acute leukemias |
| Q37374567 | MicroRNAs in the ontogeny of leukemias and lymphomas |
| Q37330733 | MicroRNAs: new players in acute myeloid leukaemia |
| Q93541677 | MicroRNAs: tiny players with a big role in the pathogenesis of leukemias and lymphomas |
| Q24528253 | Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer |
| Q36982175 | Microarray analysis of gene expression of cancer to guide the use of chemotherapeutics |
| Q25255941 | Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodology |
| Q36199867 | Microarrays and Crohn's disease: collecting reliable information |
| Q36680069 | Microarrays to identify new therapeutic strategies for cancer |
| Q36793806 | Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia |
| Q34669933 | Microfluidics for T- lymphocyte cell separation and inflammation monitoring in burn patients |
| Q36046625 | Molecular Portrait of Oral Tongue Squamous Cell Carcinoma Shown by Integrative Meta-Analysis of Expression Profiles with Validations |
| Q37165359 | Molecular assessment of depression from mRNAs in the peripheral leukocytes. |
| Q37802312 | Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. |
| Q36186561 | Molecular cytogenetics in haematological malignancy: current technology and future prospects |
| Q37809866 | Molecular diagnosis of acute myeloid leukemia |
| Q37082659 | Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks |
| Q37588387 | Molecular gene signature and prognosis of non-small cell lung cancer |
| Q38169021 | Molecular pathogenesis of AML: translating insights to the clinic |
| Q37724869 | Molecular pathways involved in loss of graft function in kidney transplant recipients. |
| Q37206155 | Molecular profiling in the age of cancer genomics |
| Q40276097 | Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations |
| Q37236994 | Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| Q40377138 | Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy |
| Q34403639 | Molecular signatures in acute myeloid leukemia. |
| Q34244973 | Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. |
| Q36586291 | Multiplex-FISH (M-FISH): technique, developments and applications |
| Q24597256 | Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia |
| Q39090287 | Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway |
| Q40902348 | Mutated genes and driver pathways involved in myelodysplastic syndromes—a transcriptome sequencing based approach |
| Q28298423 | NUP98 dysregulation in myeloid leukemogenesis |
| Q89944347 | Network Properties of Cancer Prognostic Gene Signatures in the Human Protein Interactome |
| Q37829192 | New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the Clinic |
| Q31116667 | New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures |
| Q38328340 | New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes |
| Q39900008 | Next-generation sequencing of cancer genomes: back to the future. |
| Q33414663 | Non-negative matrix factorization for the analysis of complex gene expression data: identification of clinically relevant tumor subtypes |
| Q36228053 | Normal and leukaemic stem cells |
| Q92996721 | Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies |
| Q37709333 | Notch signaling: switching an oncogene to a tumor suppressor. |
| Q41691430 | Novel harmonic regularization approach for variable selection in Cox's proportional hazards model |
| Q53632146 | Novel mutations in the FLT3 gene in adult patients with refractory acute myeloid leukemia |
| Q37810969 | Older patients with acute myeloid leukemia |
| Q41895366 | Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML. |
| Q44666362 | Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. |
| Q36163066 | Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. |
| Q36628305 | PBX3 is an important cofactor of HOXA9 in leukemogenesis |
| Q38345022 | POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature |
| Q35543402 | Pathway-based analysis of the hidden genetic heterogeneities in cancers |
| Q81170940 | Pattern robustness of diagnostic gene expression signatures in leukemia |
| Q36668271 | Perspectives of proteomics in acute myeloid leukemia |
| Q37627876 | Pharmacogenomics in acute myeloid leukemia. |
| Q34781553 | Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features |
| Q46370523 | Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. |
| Q37132871 | Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia |
| Q64085970 | Predicting Complete Remission of Acute Myeloid Leukemia: Machine Learning Applied to Gene Expression |
| Q31109949 | Predicting patient survival from microarray data by accelerated failure time modeling using partial least squares and LASSO. |
| Q47322162 | Predicting phenotypes from microarrays using amplified, initially marginal, eigenvector regression |
| Q33237070 | Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays |
| Q37059396 | Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling |
| Q40109282 | Predictive tests for individualization of pharmacological cancer treatment |
| Q46028092 | Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. |
| Q38377189 | Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia |
| Q38183943 | Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. |
| Q91199392 | Prognostic hallmarks in AML |
| Q27851726 | Prognostic relevance of integrated genetic profiling in acute myeloid leukemia |
| Q44133432 | Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia |
| Q36929806 | Progress in the treatment of acute myeloid leukemia |
| Q38324390 | Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia |
| Q33880813 | Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome |
| Q38660073 | Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers |
| Q90462212 | Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia |
| Q33244998 | Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications |
| Q33420426 | Proteomics: analysis of spectral data |
| Q33518038 | Quantitative comparison of microarray experiments with published leukemia related gene expression signatures |
| Q27851623 | RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group |
| Q33384448 | Randomization in laboratory procedure is key to obtaining reproducible microarray results |
| Q37206159 | Recent advances in the molecular diagnosis and prognosis of colorectal cancer |
| Q47565861 | Reconstruction of molecular network evolution from cross-sectional omics data |
| Q52817300 | Recurrent Cytogenetic Abnormalities in Acute Myeloid Leukemia |
| Q24634204 | Recurring mutations found by sequencing an acute myeloid leukemia genome |
| Q64103774 | Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia |
| Q37270376 | Reducing the complexity of complex gene coexpression networks by coupling multiweighted labeling with topological analysis |
| Q37450557 | Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression |
| Q37080843 | Review: genetic models of acute myeloid leukaemia |
| Q37419348 | Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia |
| Q33286957 | Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools |
| Q52566507 | Robust sparse accelerated failure time model for survival analysis. |
| Q37810111 | Role of gene-expression profiling in chronic myeloid leukemia |
| Q54652926 | Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. |
| Q34144877 | Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples |
| Q58576722 | S100 Proteins in Acute Myeloid Leukemia |
| Q37610020 | SPARC: a matricellular regulator of tumorigenesis |
| Q53515190 | SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. |
| Q92519522 | Scalable Prediction of Acute Myeloid Leukemia Using High-Dimensional Machine Learning and Blood Transcriptomics |
| Q38204373 | Semi-supervised clustering methods |
| Q34180853 | Semi-supervised recursively partitioned mixture models for identifying cancer subtypes |
| Q53590608 | Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy |
| Q51856192 | Stem cell gene expression programs influence clinical outcome in human leukemia. |
| Q36117881 | Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program |
| Q36007347 | Stratification of acute myeloid leukemia based on gene expression profiles |
| Q83645730 | Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling |
| Q47760063 | Surveillance of transcriptomes in basic military trainees with normal, febrile respiratory illness, and convalescent phenotypes. |
| Q36310257 | Systematic analysis of hematopoietic gene expression profiles for prognostic prediction in acute myeloid leukemia |
| Q38354101 | Systematic identification of transcription factors associated with patient survival in cancers |
| Q38096025 | Systems level immune response analysis and personalized medicine |
| Q34988140 | T-ReCS: stable selection of dynamically formed groups of features with application to prediction of clinical outcomes |
| Q43559106 | Testing the prediction error difference between 2 predictors |
| Q40740405 | The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies |
| Q89457595 | The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia |
| Q36591431 | The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia |
| Q38083604 | The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation |
| Q37671778 | The challenge of risk stratification in acute myeloid leukemia with normal karyotype |
| Q31033394 | The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies |
| Q88790380 | The future may be closer than you think: a response from the Personalized Medicine Coalition to the Royal Society's report on personalized medicine |
| Q24683173 | The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis |
| Q28544750 | The human immune response to tuberculosis and its treatment: a view from the blood |
| Q98566206 | The mitochondrial transcription machinery genes are upregulated in acute myeloid leukemia and associated with poor clinical outcome |
| Q57286200 | The modular network structure of the mutational landscape of Acute Myeloid Leukemia |
| Q36939043 | The molecular characterization and clinical management of multiple myeloma in the post-genome era. |
| Q34530992 | The molecular classification of multiple myeloma |
| Q33241398 | The molecular portraits of breast tumors are conserved across microarray platforms |
| Q33386662 | The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension |
| Q91752975 | The power and potential of integrated diagnostics in acute myeloid leukaemia |
| Q36148564 | The promise of molecular profiling for cancer identification and treatment |
| Q37900755 | The role of gene expression profiling in drug discovery |
| Q37738548 | The role of molecular tests in acute myelogenous leukemia treatment decisions |
| Q38198569 | The use of molecular genetics to refine prognosis in acute myeloid leukemia |
| Q36773687 | The use of transcriptomic biomarkers for personalized medicine |
| Q37271941 | Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years |
| Q51818965 | Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies |
| Q37586897 | Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia |
| Q36970214 | Transcriptional dysregulation during myeloid transformation in AML. |
| Q40075629 | Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia |
| Q36412663 | Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies |
| Q27853347 | Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade |
| Q36411676 | Translating genomic biomarkers into clinically useful diagnostics |
| Q42153188 | Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors |
| Q36101066 | Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia |
| Q35849255 | Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. |
| Q41252330 | Upregulated heme biosynthesis, an exploitable vulnerability in MYCN-driven leukemogenesis. |
| Q55291688 | Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia. |
| Q30992230 | Use of extreme patient samples for outcome prediction from gene expression data. |
| Q36607291 | Use of gene expression microarrays for the study of acute leukemia |
| Q35873673 | Using microarrays to predict resistance to chemotherapy in cancer patients |
| Q38760619 | Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. |
| Q38029546 | Vascular endothelial growth factor signaling in acute myeloid leukemia |
| Q33775647 | What are the endpoints of therapy for acute leukemias? Old definitions and new challenges |
| Q38700338 | ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells. |
| Q81399255 | [DNA-chips in the diagnosis of hematological malignancies] |
| Q42251074 | c-Met inhibition in a HOXA9/Meis1 model of CN-AML. |
| Q33936093 | ccSVM: correcting Support Vector Machines for confounding factors in biological data classification |
| Q39039867 | miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism |
| Q38313725 | siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. |
Search more.